SEER icon

Seer Inc

2.26 USD
-0.03
1.31%
At close Feb 21, 4:00 PM EST
1 day
-1.31%
5 days
-2.16%
1 month
-4.24%
3 months
-5.04%
6 months
36.97%
Year to date
-3.00%
1 year
43.95%
5 years
-96.00%
10 years
-96.00%
 

About: Seer Inc is a biotechnology company. The company commercializes transformative products for researchers to unlock deep, unbiased biological information. Its product, the Proteograph Product Suite (Proteograph), will leverage its proprietary engineered nanoparticle (NP) technology to provide unbiased, deep, rapid, and large-scale access across the proteome.

Employees: 147

0
Funds holding %
of 7,139 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

80% more call options, than puts

Call options by funds: $9K | Put options by funds: $5K

14% more capital invested

Capital invested by funds: $58.1M [Q3] → $66.5M (+$8.42M) [Q4]

11% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 9

0.96% more ownership

Funds ownership: 51.48% [Q3] → 52.43% (+0.96%) [Q4]

0% more funds holding

Funds holding: 70 [Q3] → 70 (+0) [Q4]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q3] → 1 (+0) [Q4]

17% less repeat investments, than reductions

Existing positions increased: 19 | Existing positions reduced: 23

Research analyst outlook

We haven’t received any recent analyst ratings for SEER.

Financial journalist opinion

Based on 3 articles about SEER published over the past 30 days

Neutral
GlobeNewsWire
1 day ago
Seer to Participate in the TD Cowen 45th Annual Health Care Conference
REDWOOD CITY, Calif., Feb. 21, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that the company will be participating in the upcoming TD Cowen 45th Annual Healthcare Conference in Boston, MA.
Seer to Participate in the TD Cowen 45th Annual Health Care Conference
Neutral
GlobeNewsWire
2 days ago
Seer to Feature Proteomic Advancements in Cancer and RNA Therapy Research among other Findings at US HUPO 2025
Seminar from Dr. Jinjun Shi from Brigham and Women's Hospital and Harvard Medical School to highlight study of proteomic perturbations resulting from a novel approach to cancer therapy revealed using Seer's Proteograph™ Product Suite Seminar from Dr. Jinjun Shi from Brigham and Women's Hospital and Harvard Medical School to highlight study of proteomic perturbations resulting from a novel approach to cancer therapy revealed using Seer's Proteograph™ Product Suite
Seer to Feature Proteomic Advancements in Cancer and RNA Therapy Research among other Findings at US HUPO 2025
Neutral
GlobeNewsWire
1 week ago
Seer to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025
REDWOOD CITY, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that it will report financial results for the fourth quarter and full year 2024 on Thursday, February 27, 2025. Company management will be webcasting a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Seer to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025
Neutral
GlobeNewsWire
1 month ago
Seer to Present at the J.P. Morgan 43rd Annual Healthcare Conference
REDWOOD CITY, Calif., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that the company will be participating in the upcoming J.P. Morgan 43rd Annual Healthcare Conference in San Francisco, CA.
Seer to Present at the J.P. Morgan 43rd Annual Healthcare Conference
Neutral
GlobeNewsWire
3 months ago
Seer Ranked Number 57 Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500™
Attributes 2,440% revenue growth to increased adoption of its Proteograph™ Product Suite and exciting discoveries made by Seer customers across multiple areas of biology and disease Attributes 2,440% revenue growth to increased adoption of its Proteograph™ Product Suite and exciting discoveries made by Seer customers across multiple areas of biology and disease
Seer Ranked Number 57 Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500™
Neutral
GlobeNewsWire
3 months ago
Seer to Participate in Upcoming November Investor Conferences
REDWOOD CITY, Calif., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced company management will be participating in the following investor conferences:
Seer to Participate in Upcoming November Investor Conferences
Neutral
Seeking Alpha
3 months ago
Seer, Inc. (SEER) Q3 2024 Earnings Call Transcript
Seer, Inc. (SEER) Q3 2024 Earnings Call Transcript
Seer, Inc. (SEER) Q3 2024 Earnings Call Transcript
Negative
Zacks Investment Research
3 months ago
Seer, Inc. (SEER) Reports Q3 Loss, Tops Revenue Estimates
Seer, Inc. (SEER) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to loss of $0.33 per share a year ago.
Seer, Inc. (SEER) Reports Q3 Loss, Tops Revenue Estimates
Neutral
GlobeNewsWire
3 months ago
Seer Enters into a Co-Marketing and Sales Agreement with Thermo Fisher Scientific
Collaboration enhances unprecedented access to deep, unbiased proteomics at scale, enabling deeper insights into human biology Collaboration enhances unprecedented access to deep, unbiased proteomics at scale, enabling deeper insights into human biology
Seer Enters into a Co-Marketing and Sales Agreement with Thermo Fisher Scientific
Neutral
GlobeNewsWire
3 months ago
Seer Highlights Capability of Deep Proteomics to Enhance Genomic Insights Into Alzheimer's, Lung Cancer, and More at ASHG 2024
CoLab session with PrognomiQ and Salk Institute plus multiple presentations of new data offer firsthand look at multi-omic breakthroughs powered by Seer's Proteograph™ Product Suite CoLab session with PrognomiQ and Salk Institute plus multiple presentations of new data offer firsthand look at multi-omic breakthroughs powered by Seer's Proteograph™ Product Suite
Seer Highlights Capability of Deep Proteomics to Enhance Genomic Insights Into Alzheimer's, Lung Cancer, and More at ASHG 2024
Charts implemented using Lightweight Charts™